• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Molecular basis underlying anti-tumor activity of an oncolytic measles virus

Research Project

Project/Area Number 16K20991
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeMulti-year Fund
Research Field Virology
Tumor therapeutics
Research InstitutionThe University of Tokyo

Principal Investigator

Fujiyuki Tomoko  東京大学, 生産技術研究所, 特任准教授 (50610630)

Research Collaborator KAI Chieko  
YONEDA Misako  
Project Period (FY) 2016-04-01 – 2019-03-31
Project Status Completed (Fiscal Year 2018)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2017: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Keywords腫瘍溶解性ウイルス / 麻疹ウイルス / がん / 難治性乳癌 / 細胞死 / 腫瘍溶解性麻疹ウイルス / 難治性癌 / 抗腫瘍効果 / 組換え麻疹ウイルス / 投与経路 / 抵抗性
Outline of Final Research Achievements

In this study, we aimed to evaluate anti-tumor activity of an oncolytic recombinant measles virus, rMV-SLAMblind, and to analyze molecular mechanisms of cancer cells to respond to rMV-SLAMblind therapy. By using mouse xenograft models of triple negative breast cancer cell lines, obvious anti-tumor activities of rMV-SLAMblind were observed. On the other hand, we found resistant cell lines to rMV-SLAMblind, whereas those cells express the virus receptor molecule. These cell lines have different molecular mechanisms in response to the virus infection. These results demonstrate the basis of applicability and molecular mechanisms of rMV-SLAMblind therapy.

Academic Significance and Societal Importance of the Research Achievements

癌は国内外問わず死亡者数の多い疾患であり、様々な治療法が開発されてきた。しかしながら、既存の治療法を適用できないケースも多々あるため、新たな治療法の開発が求められている。そこで近年提唱されているのが腫瘍溶解性ウイルス療法である。我々が開発中の腫瘍溶解性組換え麻疹ウイルスの難治性癌に対する抗腫瘍効果が明らかになったことは、本ウイルス療法への臨床応用への有望性を支持する。さらに、本ウイルス療法に対する細胞側の応答性に着目してより効果の発揮しやすい癌の特性を明らかとすることで、基礎ウイルス学的知見を得られるだけでなく、臨床応用時の奏功率を上げることにもつながると期待される。

Report

(4 results)
  • 2018 Annual Research Report   Final Research Report ( PDF )
  • 2017 Research-status Report
  • 2016 Research-status Report
  • Research Products

    (15 results)

All 2018 2017 2016

All Journal Article (1 results) (of which Peer Reviewed: 1 results,  Open Access: 1 results) Presentation (14 results) (of which Int'l Joint Research: 7 results)

  • [Journal Article] Measles virus selectively blind to SLAM has oncolytic efficacy against nectin-4-expressing pancreatic cancer cells.2016

    • Author(s)
      Awano M, Fujiyuki T, Shoji K, Amagai Y, Murakami Y, Furukawa Y, Sato H, Yoneda M, Kai C
    • Journal Title

      Cancer Sci

      Volume: 11 Issue: 11 Pages: 1647-1652

    • DOI

      10.1111/cas.13064

    • Related Report
      2016 Research-status Report
    • Peer Reviewed / Open Access
  • [Presentation] A recombinant SLAM-blind measles virus is a promising candidate for scirrhous gastric cancer treatment.2018

    • Author(s)
      Kai C, Shoji K, Kwon HJ, Sugai A, Yanagihara K, Yamaguchi H, Sato H, Fujiyuki T, Yoneda M.
    • Organizer
      11th International Oncolytic Virus Conference 2018
    • Related Report
      2018 Annual Research Report
    • Int'l Joint Research
  • [Presentation] A recombinant SLAMblind measles virus is applicable for breast cancer treatment.2018

    • Author(s)
      Yoneda M, Fujiyuki T, Sato H, Daigo Y, Kai C.
    • Organizer
      11th International Oncolytic Virus Conference 2018
    • Related Report
      2018 Annual Research Report
    • Int'l Joint Research
  • [Presentation] A recombinant measles virus blind to SLAM is a promising candidate for scirrhous gastric cancer therapy.2018

    • Author(s)
      Kai C, Shoji K, Kwon HJ, Sugai A, Yanagihara K, Yamaguchi H, Sato H, Fujiyuki T, Yoneda M.
    • Organizer
      XIX International meeting on Negative strand viruses
    • Related Report
      2018 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Oncolytic recombinant measles is a candidate therapeutic agent for refractory breast cancer.2018

    • Author(s)
      Fujiyuki T, Amagai Y, Shoji K, Sugai A, Awano M, Sato H, Yoneda M, Kai C.
    • Organizer
      XIX International meeting on Negative strand viruses
    • Related Report
      2018 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Anti-tumor acitivity of a recombinant oncolytic measles virus, rMV-SLAMblind, against scirrhous gastric cancer cells.2018

    • Author(s)
      Kai C, Shoji K, Kwon HJ, Sugai A, Yanagihara K, Yamaguchi H, Nakanishi T, Sato H, Fujiyuki T, Yoneda M.
    • Organizer
      第66回日本ウイルス学会
    • Related Report
      2018 Annual Research Report
  • [Presentation] An oncolytic recombinant measles virus is a candidate of a novel therapeutic agent for triple negative breast cancer.2017

    • Author(s)
      Fujiyuki T, Amagai Y, Shoji K, Sugai A, Awano M, Sato H, Yoneda M, Kai C.
    • Organizer
      XXVth European Society of Gene & Cell Therapy, Oct 17-21, Berlin, Germany.
    • Related Report
      2017 Research-status Report
    • Int'l Joint Research
  • [Presentation] Development of oncolytic measles virus, rMV-SLAMblind.2017

    • Author(s)
      Kai C, Fujiyuki T, Shoji K, Sato H, Yoneda M.
    • Organizer
      XXVth European Society of Gene & Cell Therapy, Oct 17-21, Berlin, Germany.
    • Related Report
      2017 Research-status Report
    • Int'l Joint Research
  • [Presentation] 組換え麻疹ウイルスのスキルス胃癌細胞株に対する抗腫瘍効果2017

    • Author(s)
      藤幸 知子、庄司 紘一郎、菅井 亮宏、山口 英樹、柳原 五吉、 佐藤 宏樹、米田 美佐子、甲斐 知惠子
    • Organizer
      第76回日本癌学会学術総会
    • Related Report
      2017 Research-status Report
  • [Presentation] 正常免疫マウス腫瘍モデルを用いた組換え麻疹ウイルスの抗腫瘍効果 に対する抗体の影響2017

    • Author(s)
      庄司 紘一郎、雨貝 陽介、藤幸 知子、佐藤 宏樹、米田 美佐子、甲斐 知惠子
    • Organizer
      第76回日本癌学会学術総会
    • Related Report
      2017 Research-status Report
  • [Presentation] 正常免疫腫瘍移植モデルを用いた組換え麻疹ウイルスの治療効果および免疫の影響2017

    • Author(s)
      庄司紘一郎、藤幸知子、雨貝陽介、佐藤宏樹、米田美佐子、甲斐知惠子
    • Organizer
      第160回日本獣医学会学術集会
    • Related Report
      2017 Research-status Report
  • [Presentation] 腫瘍溶解性組換え麻疹ウイルスの難治性乳癌細胞に対する抗腫瘍効果2016

    • Author(s)
      藤幸知子、雨貝陽介、庄司紘一郎、菅井亮宏、粟野睦美、佐藤宏樹、米田美佐子、甲斐知惠子
    • Organizer
      第39回日本分子生物学会年会
    • Place of Presentation
      横浜
    • Year and Date
      2016-11-30
    • Related Report
      2016 Research-status Report
  • [Presentation] Recombinant SLAM-blind measles virus is a promising candidate for triple negative breast cancer therapy.2016

    • Author(s)
      Fujiyuki T, Amagai Y, Shoji K, Kuraishi T, Sugai A, Awano M, Sato H, Hattori S, Yoneda M, Kai C.
    • Organizer
      第64回日本ウイルス学会
    • Place of Presentation
      札幌
    • Year and Date
      2016-10-23
    • Related Report
      2016 Research-status Report
  • [Presentation] 癌幹細胞様サイドポピュレーションに対する腫瘍溶解性組換え麻疹ウイルスの抗腫瘍効果解析2016

    • Author(s)
      Awano M, Fujiyuki T, Shoji K, Yoneda M, Kai C.
    • Organizer
      第75回日本癌学会学術集会
    • Place of Presentation
      横浜
    • Year and Date
      2016-10-06
    • Related Report
      2016 Research-status Report
  • [Presentation] Immunocompetent animal model to examine influence of immunity on oncolytic virotherapy with a recombinant measles virus.2016

    • Author(s)
      Shoji K, Fujiyuki T, Amagai Y, Sato H, Yoneda M, Kai C.
    • Organizer
      International Veterinary Immunology Symposium 2016
    • Place of Presentation
      ゴールドコースト(オーストラリア)
    • Year and Date
      2016-08-16
    • Related Report
      2016 Research-status Report
    • Int'l Joint Research

URL: 

Published: 2016-04-21   Modified: 2021-02-19  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi